NCT07527767

Secondary Use of PARALLEL-HF Data

Brain Natriuretic Peptide and Biomarkers of Heart Failure During Sacubitril Valsartan Treatment in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction (HFrEF): Secondary Use of PARALLEL-HF Data

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 236 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 20 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to assess the effect of sacubitril valsartan at a target dose of 200 mg b.i.d. and enalapril 10 mg b.i.d. on cardiovascular (CV) mortality and morbidity in Japanese HF patients with reduced ejection fraction.

Conditions

• Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)

Timeline

• Start date: 2022-07-27
• Primary completion: 2023-12-15
• Completion: 2023-12-15
• First posted: 2026-04-14
• Last updated: 2026-04-14

Locations

1 site across 1 country: Japan